Literature DB >> 24427768

Recommended immunization schedule for adults in Korea, by the Korean Society of Infectious Diseases, 2012.

.   

Abstract

This guideline contains the recommended immunization schedule for adults in Korea, updated in 2012. In 2007, the Korean Society of Infectious Diseases (KSID) published a textbook on adult immunization, titled 'Vaccination for Adult.' In 2012, when the second edition of the book was published, the KSID revised its previous recommendations on adult immunization.

Entities:  

Year:  2013        PMID: 24427768      PMCID: PMC3890445          DOI: 10.7774/cevr.2014.3.1.110

Source DB:  PubMed          Journal:  Clin Exp Vaccine Res        ISSN: 2287-3651


This guideline contains the recommended immunization schedule for adults in Korea. In 2007, the Korean Society of Infectious Diseases (KSID) published a textbook on adult immunization, titled 'Vaccination for Adult.' In 2012, when the second edition of the book was published, the KSID revised its previous recommendations on adult immunization. Figs. 1 and 2 show the recommended adult immunization schedule by the KSID [1-3].
Fig. 1

Adult immunization schedule 2012, recommended by the Korean Society of Infectious Diseases.

Td, tetanus and diphtheria toxoid; Tdap, tetanus, reduced diphtheria, acellular pertussis; HBsAb, hepatitis B surface antibody; IgG, immunoglobulin G.

a)Hepatitis A (high-risk group): persons with chronic liver disease; persons working at child-care facilities; medical personnel and laboratory workers with potential risk of exposure to hepatitis A virus; food handlers working at restaurants; persons traveling to or working in countries where hepatitis A is endemic; persons who receive blood products frequently; men sex with men; IV drug users; persons who contact with acute hepatitis A patients within 2 wk.

b)Hepatitis B (high-risk group): men sex with men; sexually active persons with more than one partner; human immunodeficiency virus (HIV) patients; IV drug users; household contacts and sexual partners of persons with hepatitis B virus (HBV) carrier; patients with chronic renal failure; patients with chronic liver disease; workers who are frequently exposed to HBV; clients and staff members of institutions for persons with developmental disabilities.

c)Measles-mumps-rubella (vaccination recommended for high-risk group): Although serological test (especially, for measles) can be done for laboratory evidence of immunity, vaccination without serologic test would be cost saving. High-risk group: healthcare personnel (serological test required, 2 doses); persons traveling to developing countries; family member who take care of immunocompromised patient; students who dwell in dormitory.

d)Varicella: vaccination recommended for high-risk group if serological test reveal no evidence of immunity. High-risk group: healthcare worker; family contacts of immunocompromised patients; teachers and child-care employees; students; military personnel; residents of correctional institutions; non-pregnant women with expecting pregnancy; adolescent and adult living in households with children; international travelers.

e)Meningococcal (high-risk group): persons with anatomical or functional asplenia; persons with complement component deficiencies; military personnel; (especially for recruits); laboratory workers exposed to meningococcus; persons who travel or live in an endemic area, particularly if their contact with local populations will be prolonged; college students living in dormitories. 2 dose series is recommended for adults with anatomical or functional asplenia, complement component deficiency, HIV infection; 2 doses should be administered at 0 and 2 mo. Revaccination with meningococcal conjugate vaccine every 5 yr for adults who remain at increased risk for infection.

f)Pneumococcal (high-risk group): chronic lung disease (including asthma); chronic cardiovascular disease; diabetes; chronic liver disease; chronic renal failure; nephrotic syndrome; functional or anatomical asplenia; immunocompromised patients (congenital immunodeficiency, HIV infection; leukemia, lymphoma, Hodgkin's disease, multiple myeloma, other malignancy; solid organ transplantation), (vaccinate with 3 or 4 doses of protein conjugate vaccine for hematopoietic stem cell transplants); prolonged use of high-dose corticosteroids or immunosuppressive agents; cochlear implant. One-time revaccination is recommended for persons aged 65 years or older if they were vaccinated 5 or more years previously and they were less than 65 years of age at the time of primary vaccination. One-time revaccination after 5 years is recommended for patients with chronic renal failure, nephrotic syndrome, functional or anatomical asplenia, immunocompromised conditions, prolonged use of immunosuppressive agents.

Source: adapted from Korean Society of Infectious Diseases. Vaccination for adult. 2nd ed. Seoul: MIP; 2012.

Fig. 2

Vaccinations indicated for adults based on medical conditions and other indications. HIV, human immunodeficiency virus; Td, diphtheria, tetanus, pertussis; MMR, measles-mumps-rubella.

  1 in total

1.  Milestones in history of adult vaccination in Korea.

Authors:  Myoung-Don Oh; Jong-Koo Lee
Journal:  Clin Exp Vaccine Res       Date:  2012-07-31
  1 in total
  3 in total

Review 1.  Looking back to move forward: a twenty-year audit of herpes zoster in Asia-Pacific.

Authors:  Liang-Kung Chen; Hidenori Arai; Liang-Yu Chen; Ming-Yueh Chou; Samsuridjal Djauzi; Birong Dong; Taro Kojima; Ki Tae Kwon; Hoe Nam Leong; Edward M F Leung; Chih-Kuang Liang; Xiaohong Liu; Dilip Mathai; Jiun Yit Pan; Li-Ning Peng; Eduardo Rommel S Poblete; Philip J H Poi; Stewart Reid; Terapong Tantawichien; Chang Won Won
Journal:  BMC Infect Dis       Date:  2017-03-15       Impact factor: 3.090

2.  Seroepidemiology of Hepatitis Viruses and Hepatitis B Genotypes of Female Marriage Immigrants in Korea.

Authors:  Jae Cheol Kwon; Hye Young Chang; Oh Young Kwon; Ji Hoon Park; In Soo Oh; Hyung Joon Kim; Jun Hyung Lee; Ha Jung Roh; Hyun Woong Lee
Journal:  Yonsei Med J       Date:  2018-11       Impact factor: 2.759

Review 3.  Pneumonia and Streptococcus pneumoniae vaccine.

Authors:  Gyu-Lee Kim; Seung-Han Seon; Dong-Kwon Rhee
Journal:  Arch Pharm Res       Date:  2017-07-22       Impact factor: 4.946

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.